SOPHiA Genetics (NASDAQ: SOPH) has closed an underwritten public offering of ordinary shares, raising $57.5 million in gross proceeds before underwriting discounts, commissions, and estimated offering expenses, according to a press release.

The company sold 12,104,900 ordinary shares at $4.75 per share. The underwriters fully exercised their option to purchase an additional 1,578,900 shares, which were included in the total share count.

TD Cowen acted as lead book-running manager for the offering. Guggenheim Securities served as book-running manager, while BTIG and Craig-Hallum acted as lead managers.

All shares were sold by the company. The offering was made pursuant to a registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission, which was declared effective on August 15, 2025.